{"id":458391,"date":"2021-03-16T07:06:02","date_gmt":"2021-03-16T11:06:02","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458391"},"modified":"2021-03-16T07:06:02","modified_gmt":"2021-03-16T11:06:02","slug":"first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/","title":{"rendered":"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study"},"content":{"rendered":"

<\/p>\n

First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study<\/b><\/p>\n

Veeva eConsent makes it easier for patients to understand and provide electronic informed consent<\/i><\/p>\n

Milestone accelerates industry\u2019s move toward paperless, patient-centric trials<\/i><\/p>\n

PLEASANTON, Calif.–(BUSINESS WIRE<\/a>)–Veeva Systems<\/a> (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients<\/a> application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center. Veeva eConsent is the first validated application for sites and patients that transforms the consent process from manual and paper-based to an end-to-end digital experience. Patients can review documents and protocols and provide consent via mobile phone, streamlining the experience for both patients and sites.\n<\/p>\n

\n\u201cAs one of the first sites using Veeva eConsent, we\u2019re excited to collaborate with Veeva to help the industry shift from paper to digital consent for the benefit of patients and clinical research,\u201d said Charles Sydnor, CCRA, ACRP-CP, project manager at Crofoot Research Center. \u201cVeeva eConsent makes the process easy for our patients and allows us to break down the barriers of paper and location, expanding the reach of our study.\u201d\n<\/p>\n

\nCOVID-19 accelerated the industry\u2019s move to digital solutions that enable decentralized trials and keep studies on track, speed study start-up, and improve trial execution. Veeva eConsent enables this transformation through digital consent document creation, approval, and exchange. Sites can use the application for trials across sponsors and automate the flow of consent documents to the investigator site file (ISF) for better collaboration and greater speed.\n<\/p>\n

\nWith Veeva eConsent, sponsors get real-time visibility into patient consent status, date, and version and monitors and site personnel gain remote access to trial information. Reducing the time spent on administrative tasks increases site and patient engagement throughout a study.\n<\/p>\n

\n\u201cIn just six months, we went from concept to the first patient using Veeva eConsent,\u201d said Tim Davis, vice president, MyVeeva for Patients at Veeva Systems. \u201cThis marks a major step forward for the future of paperless, patient-centric trials and we remain focused on continuing to deliver innovations that will help the industry realize this important vision.\u201d\n<\/p>\n

Attend the upcoming webinar<\/a> on April 29 to hear Crofoot discuss how Veeva eConsent helps sites run more efficient clinical trials and to learn more about Veeva Clinical Network, the industry\u2019s only solution that connects sponsors, sites, and patients to accelerate clinical research.\n<\/p>\n

Additional Information <\/b><\/p>\n

\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems
\n<\/a>
Follow @veevasystems on Twitter: twitter.com\/veevasystems<\/a><\/p>\n

About Veeva Systems<\/b><\/p>\n

\nVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com<\/a>.\n<\/p>\n

Forward-looking Statements<\/b><\/p>\n

\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210316005101\/en\/<\/a><\/span><\/p>\n

\nDeivis Mercado
\n
Veeva Systems
\n
925-226-8821
\n
deivis.mercado@veeva.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Technology Clinical Trials Software Practice Management Other Health Internet Health General Health Data Management<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study Veeva eConsent makes it easier for patients to understand and provide electronic informed consent Milestone accelerates industry\u2019s move toward paperless, patient-centric trials PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center. Veeva eConsent is the first validated application for sites and patients that transforms the consent process from manual and paper-based to an end-to-end digital experience. Patients can review documents and protocols and provide consent via mobile phone, streamlining the experience for both patients and sites. \u201cAs … <\/p>\n

Continue reading “First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458391","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFirst Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study Veeva eConsent makes it easier for patients to understand and provide electronic informed consent Milestone accelerates industry\u2019s move toward paperless, patient-centric trials PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center. Veeva eConsent is the first validated application for sites and patients that transforms the consent process from manual and paper-based to an end-to-end digital experience. Patients can review documents and protocols and provide consent via mobile phone, streamlining the experience for both patients and sites. \u201cAs … Continue reading "First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T11:06:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study\",\"datePublished\":\"2021-03-16T11:06:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/\"},\"wordCount\":780,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/\",\"name\":\"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-16T11:06:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/","og_locale":"en_US","og_type":"article","og_title":"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study - Market Newsdesk","og_description":"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study Veeva eConsent makes it easier for patients to understand and provide electronic informed consent Milestone accelerates industry\u2019s move toward paperless, patient-centric trials PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center. Veeva eConsent is the first validated application for sites and patients that transforms the consent process from manual and paper-based to an end-to-end digital experience. Patients can review documents and protocols and provide consent via mobile phone, streamlining the experience for both patients and sites. \u201cAs … Continue reading \"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T11:06:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study","datePublished":"2021-03-16T11:06:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/"},"wordCount":780,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/","name":"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-16T11:06:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210316005101r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-completes-digital-consent-with-veeva-clinical-network-in-phase-2b-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458391"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458391\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}